Store
Market for Cell and Gene Therapy Contract Manufacturing Organizations (CMOs)
Publication Date: April 12, 2021
Tags: CAR-T Cell Therapy, Cell and Gene Therapy, Contract Research and Manufacturing Orgs, COVID-19, Life Science, Pharma & Biopharma
Pages: 130
SKU: 21-023
Contract manufacturing is becoming increasingly vital in the pharmaceutical industry, particularly in cell and gene therapy due to the high demand for these innovative products. Kalorama Information’s report, Market for Cell and Gene Therapy Contract Manufacturing Organizations (CMOs), provides comprehensive insights into this dynamic market.
Report Highlights:
- Biopharmaceutical Contract Manufacturing Market: In-depth analysis of the current landscape and future trends.
- Role: Examination of the critical role CMOs play in the biopharmaceutical industry.
- Services Offered: Detailed overview of the services provided by CMOs, from development to commercialization.
- Usage Drivers: Factors driving the increased use of CMOs in cell and gene therapy.
- Profiles of Companies, Key Players, and Competitors in the Market: Detailed profiles of leading companies in the CMO market.
- COVID-19’s Challenges and Opportunities for CMOs: Analysis of the impact of the pandemic on CMOs, including challenges and new opportunities.
- Global and Regional Market Overviews—U.S., Europe, and Other Nations: Comprehensive market overviews by region.
- New Developments and Advancing Technology: Insights into the latest technological advancements and their implications for CMOs.
- Development Pipeline: Overview of the development pipeline for cell and gene therapy products.
- Production Issues: Examination of common production challenges and strategies to overcome them.
- Cost: Analysis of cost structures and economic considerations in CMO services.
- Logistics: Insights into logistics and supply chain management for CMOs.
- Mergers and Acquisitions: Exploration of recent M&A activities and their impact on the market.
Company Profiles:
Kalorama profiles a select group of companies that are representative of the market or handle a large volume, providing a thorough understanding of the competitive landscape.
Table: Cell and Gene Therapy Market Summary, by Product Segment, 2015-2025 ($ millions)
| Year | Dermatology | Cardiovascular | Oncology | Ophthalmolog | Musculoskeletal | Other | Total |
| 2015 | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million |
| 2016 | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million |
| 2017 | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million |
| 2018 | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million |
| 2019 | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million |
| 2020 | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million |
| 2021 | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million |
| 2022 | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million |
| 2023 | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million |
| 2024 | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million |
| 2025 | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million | $XX Million |
| CAGR 2015-2020 |
XX% | XX% | XX% | XX% | XX% | XX% | XX% |
| CAGR 2015-2025 |
XX% | XX% | XX% | XX% | XX% | XX% | XX% |
| CAGR 2020-2025 |
XX% | XX% | XX% | XX% | XX% | XX% | XX% |
Source: Kalorama Information
For further details and to purchase directly, please contact us.
Table of Contents
Chapter 1: Executive Summary
Overview
Scope and Methodology
Covid 19
Market Overview and Potential
- Cell and Gene Therapy Market
- BCMO Market
- Cell and Gene Therapy BCMO Market
Chapter 2: Introduction to Cell and Gene Therapy
Introduction
- Cell Therapy
- Gene Therapy
- Viral Vector System and New Developments
- Non-viral Systems for Transporting Genes
- End Users
- Hospitals
- Research Institutes
- Wound Care Centers
- Cancer Centers
Chapter 3: Cell and Gene Therapy Industry – Product Pipeline, Production & Key Players
Overview
- Regulatory Pathway
- Priority Review
- Accelerated Approval
- Fast Track
- Breakthrough Therapy
- Orphan Drug
- Individualized Gene Therapy Approval Process
- Development Pipeline
- Production Issues
- Manufacturing Process for CAR-T
- Advancements and Barriers in Manufacturing Processes
- Cost
- Timing
- Logistics
- Capacity Shortfall
- In-House Manufacturing
- Staffing
- Key Players
- Mergers and Acquisitions
Chapter 4: Cell and Gene Therapy Markets
Overview
- Global Cell and Gene Therapy Markets
- Regional Market Overview
- United States
- Europe/European Union
- Other Countries
- Leading Competitors
Chapter 5: Biopharma Contract Manufacturing
Introduction
- The Role of BCMOs
- Services Offered by BCMOs
- Usage Drivers
- Growth Constraints
Chapter 6: Biopharma Contract Manufacturing Markets
Overview
- Global BCMO Markets
- Regional Market Overview
- United States
- Europe/European Union
- Other Countries
- Leading Competitors
Chapter 7: Cell & Gene Therapy Contract Manufacturing
Introduction
- Advancing Technology
- Dearth of Intellectual Capital
- cGMP Compliance
- Quality by Design
Chapter 8: The Market for Cell & Gene Therapy Contract Manufacturing
Overview
- Global Cell and Gene Therapy BCMO Market
- Market by Therapeutic Indication
- Market by Method
- Market by Manufacturing Stage
- Market by Global Region
- Leading Competitors
- Mergers and Acquisitions
Chapter 9: Key Players in the Cell & Gene Therapy CMO Market
- AGC Biologics
- Ajinomoto Bio-Pharma Services
- Anemocyte
- Astellas
- BioNTech IMFS
- Boehringer Ingelheim BioXcellence
- Bristol Myers Squibb
- Catalent
- Cognate BioServices/CRL
- Cytiva
- Cytovance Biologics
- Fresenius Kabi Product Partnering
- FUJIFILM Cellular Dynamics
- FUJIFILM Diosynth Biotechnologies
- Grifols
- Lonza
- Millipore Sigma/BioReliance
- Minaris Regenerative Medicine
- Novartis
- Oxford Biomedica
- Patheon/Thermo Fisher Scientific
- Pfizer CentreOne
- Porton Biologics
- Syngene International
- Takara Bio
- Takeda
- The Center for Breakthrough Medicines
- Vibalogics
- WuXi AppTec
- WuXi Biologics
- Yposkesi
Related products
Hematology and Coagulation Markets, 2023
April 5, 2023
Discover the lucrative $10 billion-dollar market for hematology and coagulation in vitro diagnostic (IVD) testing with Kalorama’s comprehensive report, Hematology and Coagulation Markets, 2023. This analysis delves into the dynamic growth factors driving this market, including new technologies, the aging population, and the increasing demand for decentralized testing.
Key Insights Provided:
- Market sizing…
Price range: $3,000.00 through $4,500.00
30-Country In Vitro Diagnostic (IVD) Market Atlas [October 2023 Update]
October 27, 2023
The in vitro diagnostics (IVD) market is a global multi-billion-dollar industry, with significant revenue generated outside the United States. To facilitate successful business planning, it’s crucial to assess regional and country-level IVD markets. Kalorama’s 30 Country IVD Market Atlas report offers detailed insights into international markets, aiding in forecast modeling and strategic planning.
Key…
Price range: $5,000.00 through $7,500.00
Cell and Gene Therapy Deals Analysis, 2021-2024
June 3, 2024
Kalorama Information’s Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024 offers a comprehensive look at the dynamic and rapidly evolving cell and gene therapy market. This report highlights the significant deal-making activities that have taken place from Q1 2021 to Q1 2024, providing valuable insights for companies and…
Price range: $6,300.00 through $9,450.00
